Clinical trials
Acute Lymphoblastic Leukemia clinical trials
Below are recruiting acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 398 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05501899RecruitingEarly Phase 1
Levocarnitine to protect the liver during ALL chemotherapy
This early-phase study tests whether levocarnitine can reduce liver injury from a chemotherapy medicine called asparaginase in people with high-risk acute lymphoblastic leukemia (ALL). If you’re eligible, you would take levocarnitine by mouth alongside your planned standard cancer treatment to see if the liver stays healthier.
Orange, CaliforniaAges 5–29 - NCT05519579RecruitingPhase 2
Spinal chemotherapy to help protect the brain during blinatumomab
This trial studies giving medicine into the spinal fluid (intrathecal chemotherapy) to lower the risk of brain/nerve side effects from blinatumomab. It’s for adults with certain types of B-cell acute lymphoblastic leukemia (ALL) who are starting their first cycle.
Atlanta, GeorgiaAges 18 years+ - NCT05535855RecruitingPhase 1
UCD19 CAR T for adult ALL with MRD in remission
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
Aurora, ColoradoAges 18 years+ - NCT05581030RecruitingPhase 1
Newly diagnosed ALL: testing a treatment after Hyper-CVAD
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Tampa, FloridaAges 18–50 - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT05679895RecruitingPhase 1
Study drug OC-1 for CD1a-positive T-ALL or T-LL after relapse
This Phase 1 trial tests the safety and early signs of benefit of OC-1 in people with relapsed or hard-to-treat T-cell leukemia/lymphoma (T-ALL/LL) that has a CD1a marker. You may be considered if standard treatments didn’t work or the cancer returned, and if your organs and infections are controlled.
BarcelonaAges 2 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Birmingham, AlabamaAges 6–39 - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05792007Recruiting
Study of bone marrow environment in childhood leukemia
This study looks at what the bone marrow “microenvironment” is like in children newly diagnosed with acute leukemia, to better understand the disease. It also compares leukemia samples to samples from children having certain orthopedic surgery.
ToursAges 1–15 - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Phoenix, ArizonaAges Up to 1 year - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05884333RecruitingPhase 2
Cord blood transplant for adults with blood cancer
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
New York, New YorkAges 21–65 - NCT05929976Recruiting
Study of gut and blood chemistry in children with new leukemia
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
New York, New YorkAges 3–18 - NCT05959720Recruiting
Teen-to-adult ALL study using a pediatric chemotherapy plan
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
São Paulo, São PauloAges 16–50 - NCT05995028RecruitingPhase 1
CAR-T therapy for CD7-positive blood cancers
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 398 recruiting acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.